Market Overview

Teva Holders Shrug at FDA Approval of Generic-Version of Novartis' TOBI in US

Related TEVA
Does Teva Pharmaceutical's New Executive Hint At A Coming M&A Deal?
Morning Market Gainers
Bernstein raises Teva price target; company eyeing acquistions (Seeking Alpha)
Related NVS
Novartis International AG: New Novartis data shows Cosentyx is significantly superior to Stelara and clears skin (PASI 90
8 Healthcare Names Cowen & Co Are Talking About

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces today that the U.S. Food and Drug Administration has granted approval of the generic equivalent to TOBI^® (Tobramycin Inhalation Solution USP) in the United States. Pursuant to an agreement with Novartis (NYSE: NVS) on this product, Teva expects to launch this product in late November. Marketed by Novartis, TOBI^® had annual sales of approximately $350 million in the United States, according to IMS data as of June 30, 2013.

Posted-In: News FDA


Related Articles (TEVA + NVS)

Around the Web, We're Loving...